Published in
American Society of Hematology, Blood, 10(128), p. 1382-1395, 2016
DOI: 10.1182/blood-2016-03-707414
Links
- ORCID
- American Society of Hematology | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia
Journal article published in 2016 by
Seong Lin Khaw 
,
Santi Suryani,
Kathryn Evans,
Jennifer Richmond,
Alissa Robbins,
Raushan T. Kurmasheva,
Catherine A. Billups,
Stephen W. Erickson,
Yuelong Guo ,
Peter J. Houghton,
Malcolm A. Smith,
Hernan Carol,
Andrew W. Roberts,
David C. S. Huang,
Richard B. Lock
,
Santi Suryani,
Kathryn Evans,
Jennifer Richmond,
Alissa Robbins,
Raushan T. Kurmasheva,
Catherine A. Billups,
Stephen W. Erickson,
Yuelong Guo ,
Peter J. Houghton,
Malcolm A. Smith,
Hernan Carol,
Andrew W. Roberts,
David C. S. Huang,
Richard B. Lock
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points Venetoclax demonstrates potent in vitro and in vivo single-agent activity in MLL-rearranged ALL xenografts. Clinically efficacious BH3-mimetic therapy for other high-risk ALL subtypes is likely to require concurrent BCL-2 and BCL-XL inhibition.